36results about How to "Suppress cloning" patented technology

The invention relates to the field of medical intermediates and anti-tumor drugs, in particular to a terpyridyl ligand containing nitrogen mustard and a preparation method and application of the terpyridyl ligand. The preparation method comprises the following steps: by taking N, N-bis (2-hydroxyethyl)-aniline as a raw material, carrying out Vilsmeier-Haack reaction to prepare an aromatic aldehyde intermediate containing nitrogen mustard, and then further reacting with 2-acetylpyridine to prepare the terpyridyl ligand L1 containing nitrogen mustard. The method is simple and feasible, has low requirements on equipment, and is easy to separate and purify target compounds. The compound has high symmetry in structure, and is a terpyridyl derivative which has the simplest structure and contains aromatic nitrogen mustard at present. Various metal complexes containing nitrogen mustard can be designed as ligands of various metal ions. In-vitro anti-tumor experiments show that the compound has the characteristics of excellent anti-tumor effect, capability of effectively inhibiting growth, migration, crawling, cloning and the like of tumor cells, and has wide research and development values in the field of anti-tumor drugs.

The invention belongs to the field of biomedical research, and in particular relates to the use of human EDDM3A gene as a target in the preparation of drugs for treating gastric cancer. After extensive and in-depth research, the present invention finds that down-regulating the expression of human EDDM3A gene by RNAi method can effectively inhibit the proliferation of gastric cancer cells, promote cell apoptosis, and effectively control the growth process of gastric cancer. The siRNA provided by the present invention or the nucleic acid construct containing the siRNA sequence, lentivirus can specifically inhibit the proliferation rate of gastric cancer cells, promote the apoptosis of gastric cancer cells, inhibit the cloning of gastric cancer cells, inhibit the metastasis ability of gastric cancer cells, and inhibit the growth of gastric cancer, thereby treating Gastric cancer, opening up a new direction for the treatment of gastric cancer.

The invention relates to the fields of pharmaceutical intermediates and antineoplastic drugs, in particular to a terpyridine ligand of nitrogen mustard and its preparation method and application. Using N,N-bis(2-hydroxyethyl)-aniline as raw material, the aromatic aldehyde intermediate of nitrogen mustard was prepared by Vilsmeier-Haack reaction, and then further reacted with 2-acetylpyridine to prepare the terpyridine ligand of nitrogen mustard L1. The method is simple and easy to implement, has low requirements on equipment, and is easy to separate and purify the target compound. The compound has good symmetry in structure, and is currently the terpyridine derivative with the simplest structure and aromatic nitrogen mustard. It can be used as a ligand for various metal ions to design various metal complexes of nitrogen mustards. In vitro anti-tumor experiments show that the compound has excellent anti-tumor effect, can effectively inhibit the growth, migration, crawling and cloning of tumor cells, and has extensive research and development value in the field of anti-tumor drugs.

The invention belongs to the field of biomedical research, and specifically relates to the use of human LSM5 gene as a target in the preparation of colorectal cancer treatment drugs. After extensive and in-depth research, the present invention finds that the RNAi method can effectively inhibit the proliferation of colorectal cancer cells, promote cell apoptosis, and effectively control the growth process of colorectal cancer after down-regulating the expression of human LSM5 gene. The siRNA provided by the present invention or the nucleic acid construct containing the siRNA sequence, and the lentivirus can specifically inhibit the proliferation rate and proliferation ability of colorectal cancer cells, promote the apoptosis of colorectal cancer cells, inhibit the cloning of colorectal cancer cells, and inhibit the cloning of colorectal cancer cells. Cancer growth, so as to treat colorectal cancer, open up a new direction for the treatment of colorectal cancer.

The invention belongs to the field of biomedical research, and particularly relates to application of a human TTLL4 gene as a target in preparation of lung cancer treatment drugs. Results of wide anddeep research show that proliferation of lung cancer cells can be effectively inhibited, cell apoptosis is promoted and the growth process of the lung cancer can be effectively controlled after expression of the human TTLL4 gene is down-regulated by adopting an RNAi method. An siRNA or a nucleic acid construct and a lentivirus containing the siRNA sequence provided by the invention can specifically inhibit the proliferation rate of lung cancer cells, promote apoptosis of the lung cancer cells, inhibit cloning of the lung cancer cells, inhibit invasion of the lung cancer cells, inhibit metastasis of the lung cancer cells and inhibit growth of the lung cancer cells; therefore, a new direction is opened up for lung cancer treatment.

The invention belongs to the field of the biopharmaceutical research, and particularly relates to application of a MTHFD1L (methylenetetrahydrofolate dehydrogenase (NADP+dependent)1like) inhibitor. Bywide and deep research, the invention shows that MTHFD1L can be used as a tongue squamous cell carcinoma treatment target for the first time. The MTHFD1L inhibitor can inhibit cell multiplication oftongue squamous cell carcinoma, promote cell apoptosis of tongue squamous cell carcinoma, inhibit cell cloning, inhibit tumorigenesis of tongue squamous cell carcinoma, treat tongue squamous cell carcinoma and develops a new direction for treatment of tongue squamous cell carcinoma.

The invention relates to a traditional Chinese medicine oral liquid for treating leukemia, which is prepared by the following medicines in parts by weight: 1-10 parts of antelope's horn, 0.5-5 parts of bezoar, 1-10 parts of resina draconis, 10-200 parts of honeysuckle, 5-40 parts of largehead atractylodes rhizome, 10-40 parts of poria cocos, 10-80 parts of oldenlandia, 10-40 parts of radix ranunculi ternate, 5-30 parts of powdery paris polyphylla, 5-30 parts of edible tulip, 0.01-0.1 parts of arenobufagin, 2-20 parts of American ginseng, 2-10 parts of indigo naturalis, 3-10 parts of panax notoginseng, 5-20 parts of fructus lycii, 1-10 parts of cordyceps sinensis, 2-20 parts of flos carthami, 5-30 parts of angelica sinensis, and 5-20 parts of hippocampus. The traditional Chinese medicine oral liquid is prepared by adding an approximate amount of water into the abovementioned high-quality traditional Chinese medicinal materials to decoct for 30 minutes, obtaining the decoction after filtrating, repeatedly decocting the traditional Chinese medicinal materials for three times in this way, and obtaining the traditional Chinese medicine oral liquid for treating leukemia after concentrating and filling the liquid medicine filtered out at three times into bottles. The traditional Chinese medicine oral liquid has the advantages of being good in curative effect, free from relapse and tolerance, and low in toxic and side effects.

The invention discloses regulatory-CIAPIN1 gene recombinant adenovirus and a preparation method and use thereof. The recombinant adenovirus is obtained by inserting a CIAPIN1 gene expression cassette into the genome of a replication-deficient type-5 adenovirus, wherein the CIAPIN1 gene expression cassette consists of a survivin promoter, a CIAPIN1 gene and a terminator; and the expression of the CIAPIN1 gene is regulated by the survivin promoter. The recombinant adenovirus has high selectivity and specificity; by regulating the expression of the CIAPIN1 gene through the tumor specific survivin, the CIAPIN1 gene can be selectively expressed in glioma cells to inhibit cell cloning and induce cell apoptosis; and thus, glioma cells can be accurately killed with less damage to normal tissue cells. In-vivo experiments indicate that the regulatory-CIAPIN1 gene recombinant adenovirus can inhibit the growth of glioma cells and prolong the average survival period of tumor bearing nude mice; therefore, the regulatory-CIAPIN1 gene recombinant adenovirus can be used for preparing medicines for treating glioma and has a good development and application prospect in the field of gene therapy of glioma.

The invention, which belongs to the field of biomedical research, particularly relates to application of a human LSM5 gene as a target in preparation of a colorectal cancer treatment drug. The wide and deep research discovers that the proliferation of colorectal cancer cells can be effectively inhibited and the apoptosis can be promoted by reducing the expression of the human LSM5 gene based on anRNAi method, thereby effectively controlling the growth process of colorectal cancer. According to the invention, the siRNA or the nucleic acid construct containing the siRNA sequence and the lentivirus can specifically inhibit the proliferation rate and proliferation capacity of colorectal cancer cells, promote apoptosis of the colorectal cancer cells, inhibit cloning of the colorectal cancer cells and inhibit growth of the colorectal cancer cells, so that the colorectal cancer is treated and a new direction is opened up for colorectal cancer treatment.